Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label induction study of ravagalimab in moderate to severe ulcerative colitis after prior therapy failure
2018-000930-37Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ravagalimab in autoimmune colitis, sponsored by AbbVie Inc. Primary endpoint: Endoscopic improvement at Week 8. Started Oct 2018; status: terminated.
02
Drugs
ravagalimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2018-000930-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000930-37.